Expression of EndothelinA Receptors in Human Gliomas and Meningiomas, with High Affinity for the Selective Antagonist PD156707

Expression of EndothelinA Receptors in Human Gliomas and Meningiomas, with High Affinity for the... AbstractOBJECTIVE:Endothelin (ET) immunoreactivity, ET production, and specific ET receptors have been identified in the brain. Changes in ET concentration or receptor expression have been implicated in the pathophysiological changes in vasospasm after subarachnoid hemorrhage and in cerebral neoplasia. In this study, we have characterized the ETa and ETB receptor subtypes present in human normal cerebral cortex (NCC) and two common central nervous system tumors, i.e., meningioma (MNG) and glioblastoma multiforme (GBM). A knowledge of the ET receptor subtypes present may provide a novel therapeutic target for newly developed ET antagonists.METHODS:Saturation, competition, and autoradiographic studies were performed with the subtype-specific radioligands 125I-PD151242 and 125I-BQ3020, to characterize the ETA and ETB receptors present in NCC, MNG, andGBM.RESULTS:NCC expresses high-affinity ETA receptors on pial and intraparenchymal vessels and high-affinity ETB receptors on glia and neurons. MNGs express mainly (85%) high-affinity ETA receptors in a diffuse pattern, whereas GBMs express high-affinity ETA receptors on the neovasculature and ETB receptors on the nonvascular elements. The ET antagonist PD156707 (Kd = 0.059 nmol/L) showed a higher affinity for the ETA receptor subtype than did bosentan (Kd = 1.1 nmol/L).CONCLUSION:ETA receptors are expressed in high concentrations in MNGs and in the vasculature of NCC and GBMs. The ETA-selective antagonist PD156707 may be of potential therapeutic value in vascular and neoplastic diseases of the central nervous system. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Neurosurgery Oxford University Press

Expression of EndothelinA Receptors in Human Gliomas and Meningiomas, with High Affinity for the Selective Antagonist PD156707

Expression of EndothelinA Receptors in Human Gliomas and Meningiomas, with High Affinity for the Selective Antagonist PD156707

EXPER IM EN TA L S T U D IE S Expression of EndothelinA Receptors in Human Gliomas and Meningiomas, with High Affinity for the Selective Antagonist P D 1 5 6 7 0 7 Spencer P. Harland, F.R.C.S.(S.N.), Rhoda E. Kuc, E>.Sc., John D. Pickard, M.Chir., F.R.C.S., Anthony P. Davenport, Ph.D. A cad em ic Department of Neurosurgery (SPH, )DP) and C lin ic a l Pharm acology Unit (REK, A PD ), University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom ’t )1 fc OBJECTIVE: Endothelin (ET) immunoreactivity, ET production, and specific ET receptors have been identified in the brain. Changes in ET concentration or receptor expression have been implicated in the pathophysiological changes in vasospasm after subarachnoid hemorrhage and in cerebral neoplasia. In this study, we have charac­ terized the ETa and ETB receptor subtypes present in human normal cerebral cortex (NCC) and two common central nervous system tumors, i.e., meningioma (MNG) and glioblastoma multiforme (GBM). A knowledge of the ET receptor subtypes present may provide a novel therapeutic target for newly developed ET antagonists. METHODS: Saturation, competition, and autoradiographic studies were performed with the subtype-specific radio­ ). ligands 12>I-PD151242 and 12>I-BQ3020, to characterize the ETA and ETB receptors present in NCC, MNG, and GBM. RESULTS: NCC expresses high-affinity ETA receptors on pial and intraparenchymal vessels and high-affinity ETB receptors on glia and neurons. MNGs express mainly (85%) high-affinity ETA receptors in a diffuse pattern, whereas GBMs express high-affinity ETA receptors on the neovasculature and ETB receptors on the nonvascular elements. The ET antagonist PD156707 (Kd = 0.059 nmol/L) showed a higher affinity for the ET A receptor subtype than did bosentan (Kd = 1.1 nmol/L). CO N CLU SIO N : ETA receptors are expressed in high concentrations in MNGs and in the vasculature of NCC and < t GBMs. The ETA-selective antagonist...
Loading next page...
 
/lp/ou_press/expression-of-endothelina-receptors-in-human-gliomas-and-meningiomas-qrmpwArXBo
Publisher
Congress of Neurological Surgeons
Copyright
© Published by Oxford University Press.
ISSN
0148-396X
eISSN
1524-4040
D.O.I.
10.1097/00006123-199810000-00097
Publisher site
See Article on Publisher Site

Abstract

AbstractOBJECTIVE:Endothelin (ET) immunoreactivity, ET production, and specific ET receptors have been identified in the brain. Changes in ET concentration or receptor expression have been implicated in the pathophysiological changes in vasospasm after subarachnoid hemorrhage and in cerebral neoplasia. In this study, we have characterized the ETa and ETB receptor subtypes present in human normal cerebral cortex (NCC) and two common central nervous system tumors, i.e., meningioma (MNG) and glioblastoma multiforme (GBM). A knowledge of the ET receptor subtypes present may provide a novel therapeutic target for newly developed ET antagonists.METHODS:Saturation, competition, and autoradiographic studies were performed with the subtype-specific radioligands 125I-PD151242 and 125I-BQ3020, to characterize the ETA and ETB receptors present in NCC, MNG, andGBM.RESULTS:NCC expresses high-affinity ETA receptors on pial and intraparenchymal vessels and high-affinity ETB receptors on glia and neurons. MNGs express mainly (85%) high-affinity ETA receptors in a diffuse pattern, whereas GBMs express high-affinity ETA receptors on the neovasculature and ETB receptors on the nonvascular elements. The ET antagonist PD156707 (Kd = 0.059 nmol/L) showed a higher affinity for the ETA receptor subtype than did bosentan (Kd = 1.1 nmol/L).CONCLUSION:ETA receptors are expressed in high concentrations in MNGs and in the vasculature of NCC and GBMs. The ETA-selective antagonist PD156707 may be of potential therapeutic value in vascular and neoplastic diseases of the central nervous system.

Journal

NeurosurgeryOxford University Press

Published: Oct 1, 1998

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial